Cargando…
Changes in clinical disease activity are weakly linked to changes in MRI inflammation on treat-to-target escalation of therapy in rheumatoid arthritis
BACKGROUND: Rheumatoid arthritis (RA) treat-to-target (T2T) regimens often use the disease activity score (28 joints) incorporating C-reactive protein (DAS28(CRP)) as an outcome measure. We compared changes in the DAS28(CRP) with changes in magnetic resonance imaging (MRI) inflammation on treatment...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5655857/ https://www.ncbi.nlm.nih.gov/pubmed/29065903 http://dx.doi.org/10.1186/s13075-017-1433-7 |
_version_ | 1783273616595484672 |
---|---|
author | McQueen, Fiona M. Chapman, Peter Pollock, Terina D’Souza, Dena Lee, Arier C. Dalbeth, Nicola Stamp, Lisa Lindsay, Karen Doyle, Anthony |
author_facet | McQueen, Fiona M. Chapman, Peter Pollock, Terina D’Souza, Dena Lee, Arier C. Dalbeth, Nicola Stamp, Lisa Lindsay, Karen Doyle, Anthony |
author_sort | McQueen, Fiona M. |
collection | PubMed |
description | BACKGROUND: Rheumatoid arthritis (RA) treat-to-target (T2T) regimens often use the disease activity score (28 joints) incorporating C-reactive protein (DAS28(CRP)) as an outcome measure. We compared changes in the DAS28(CRP) with changes in magnetic resonance imaging (MRI) inflammation on treatment escalation. METHODS: Eighty seropositive RA patients with active disease were enrolled. Group A (N = 57) escalated to another conventional disease-modifying therapy (cDMARD) combination, and Group B (N = 23) to anti-TNF therapy/cDMARDs. Contrast-enhanced 3T-MRI wrist scans were obtained before and 4 months after regimen change. Scan pairs were scored for inflammation (MRI(i)) and damage. Disease activity was assessed using the DAS28(CRP). RESULTS: Eighty patients were enrolled and 66 MRI scan pairs were available for analysis. Intra-reader reliability was high: intraclass correlation coefficient (average) 0.89 (0.56–0.97). ΔDAS28(CRP) did not differ between groups: Group A, −0.94 (−3.30, 1.61); Group B, −1.53 (−3.59, 0.56) (p = 0.45). ΔMRI(i) also did not differ: Group A, 0 (−25, 10); Group B, −1 (−15, 28) (p = 0.12). Combining groups, ΔMRI(i) correlated weakly with ΔDAS28(CRP) (Spearman’s 0.36, p = 0.003). Using multiple linear regression analysis adjusting for confounders, ΔDAS28(CRP) was associated with ΔMRI(i) (p = 0.056). Of the individual MRI measures, only Δtenosynovitis correlated with ΔDAS28(CRP) (Spearman’s 0.33, p = 0.007). ΔMRI(i) was negatively associated with the MRI erosion score at entry (p = 0.0052). CONCLUSIONS: We report the first study investigating the link between changes in clinical and imaging inflammation in a real-world RA cohort escalating to conventional and biologic DMARDs. The association was significant but relatively weak, suggesting that MRI targets cannot yet be advocated as outcomes for T2T escalation. TRIAL REGISTRATION: ANZCTR 12614000895684. Registered 22 August 2014. |
format | Online Article Text |
id | pubmed-5655857 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-56558572017-10-31 Changes in clinical disease activity are weakly linked to changes in MRI inflammation on treat-to-target escalation of therapy in rheumatoid arthritis McQueen, Fiona M. Chapman, Peter Pollock, Terina D’Souza, Dena Lee, Arier C. Dalbeth, Nicola Stamp, Lisa Lindsay, Karen Doyle, Anthony Arthritis Res Ther Research Article BACKGROUND: Rheumatoid arthritis (RA) treat-to-target (T2T) regimens often use the disease activity score (28 joints) incorporating C-reactive protein (DAS28(CRP)) as an outcome measure. We compared changes in the DAS28(CRP) with changes in magnetic resonance imaging (MRI) inflammation on treatment escalation. METHODS: Eighty seropositive RA patients with active disease were enrolled. Group A (N = 57) escalated to another conventional disease-modifying therapy (cDMARD) combination, and Group B (N = 23) to anti-TNF therapy/cDMARDs. Contrast-enhanced 3T-MRI wrist scans were obtained before and 4 months after regimen change. Scan pairs were scored for inflammation (MRI(i)) and damage. Disease activity was assessed using the DAS28(CRP). RESULTS: Eighty patients were enrolled and 66 MRI scan pairs were available for analysis. Intra-reader reliability was high: intraclass correlation coefficient (average) 0.89 (0.56–0.97). ΔDAS28(CRP) did not differ between groups: Group A, −0.94 (−3.30, 1.61); Group B, −1.53 (−3.59, 0.56) (p = 0.45). ΔMRI(i) also did not differ: Group A, 0 (−25, 10); Group B, −1 (−15, 28) (p = 0.12). Combining groups, ΔMRI(i) correlated weakly with ΔDAS28(CRP) (Spearman’s 0.36, p = 0.003). Using multiple linear regression analysis adjusting for confounders, ΔDAS28(CRP) was associated with ΔMRI(i) (p = 0.056). Of the individual MRI measures, only Δtenosynovitis correlated with ΔDAS28(CRP) (Spearman’s 0.33, p = 0.007). ΔMRI(i) was negatively associated with the MRI erosion score at entry (p = 0.0052). CONCLUSIONS: We report the first study investigating the link between changes in clinical and imaging inflammation in a real-world RA cohort escalating to conventional and biologic DMARDs. The association was significant but relatively weak, suggesting that MRI targets cannot yet be advocated as outcomes for T2T escalation. TRIAL REGISTRATION: ANZCTR 12614000895684. Registered 22 August 2014. BioMed Central 2017-10-24 2017 /pmc/articles/PMC5655857/ /pubmed/29065903 http://dx.doi.org/10.1186/s13075-017-1433-7 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article McQueen, Fiona M. Chapman, Peter Pollock, Terina D’Souza, Dena Lee, Arier C. Dalbeth, Nicola Stamp, Lisa Lindsay, Karen Doyle, Anthony Changes in clinical disease activity are weakly linked to changes in MRI inflammation on treat-to-target escalation of therapy in rheumatoid arthritis |
title | Changes in clinical disease activity are weakly linked to changes in MRI inflammation on treat-to-target escalation of therapy in rheumatoid arthritis |
title_full | Changes in clinical disease activity are weakly linked to changes in MRI inflammation on treat-to-target escalation of therapy in rheumatoid arthritis |
title_fullStr | Changes in clinical disease activity are weakly linked to changes in MRI inflammation on treat-to-target escalation of therapy in rheumatoid arthritis |
title_full_unstemmed | Changes in clinical disease activity are weakly linked to changes in MRI inflammation on treat-to-target escalation of therapy in rheumatoid arthritis |
title_short | Changes in clinical disease activity are weakly linked to changes in MRI inflammation on treat-to-target escalation of therapy in rheumatoid arthritis |
title_sort | changes in clinical disease activity are weakly linked to changes in mri inflammation on treat-to-target escalation of therapy in rheumatoid arthritis |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5655857/ https://www.ncbi.nlm.nih.gov/pubmed/29065903 http://dx.doi.org/10.1186/s13075-017-1433-7 |
work_keys_str_mv | AT mcqueenfionam changesinclinicaldiseaseactivityareweaklylinkedtochangesinmriinflammationontreattotargetescalationoftherapyinrheumatoidarthritis AT chapmanpeter changesinclinicaldiseaseactivityareweaklylinkedtochangesinmriinflammationontreattotargetescalationoftherapyinrheumatoidarthritis AT pollockterina changesinclinicaldiseaseactivityareweaklylinkedtochangesinmriinflammationontreattotargetescalationoftherapyinrheumatoidarthritis AT dsouzadena changesinclinicaldiseaseactivityareweaklylinkedtochangesinmriinflammationontreattotargetescalationoftherapyinrheumatoidarthritis AT leearierc changesinclinicaldiseaseactivityareweaklylinkedtochangesinmriinflammationontreattotargetescalationoftherapyinrheumatoidarthritis AT dalbethnicola changesinclinicaldiseaseactivityareweaklylinkedtochangesinmriinflammationontreattotargetescalationoftherapyinrheumatoidarthritis AT stamplisa changesinclinicaldiseaseactivityareweaklylinkedtochangesinmriinflammationontreattotargetescalationoftherapyinrheumatoidarthritis AT lindsaykaren changesinclinicaldiseaseactivityareweaklylinkedtochangesinmriinflammationontreattotargetescalationoftherapyinrheumatoidarthritis AT doyleanthony changesinclinicaldiseaseactivityareweaklylinkedtochangesinmriinflammationontreattotargetescalationoftherapyinrheumatoidarthritis |